AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wickman, P. A.
Right arrow Articles by Thomson, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wickman, P. A.
Right arrow Articles by Thomson, K. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 796-798, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.796-798.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of DX-619, a Novel Des-Fluoro(6) Quinolone, against a Panel of Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms{dagger}

Paul A. Wickman,* Ellen Smith Moland, Jennifer A. Black, and Kenneth S. Thomson

Creighton University School of Medicine, Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, Omaha, Nebraska

Received 22 September 2005/ Returned for modification 22 November 2005/ Accepted 29 November 2005

The in vitro activities of DX-619 and four other quinolones were compared against Streptococcus pneumoniae mutants that contained a variety of alterations within the quinolone resistance-determining regions. DX-619 was the most potent quinolone and was least affected by the mutations.

* Corresponding author. Mailing address: Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178. Phone: (402) 280-2921. Fax: (402) 280-1875. E-mail: pwickman{at}creighton.edu.

{dagger} Supplemental material for this article may be found at http://aac.asm.org/.

Antimicrobial Agents and Chemotherapy, February 2006, p. 796-798, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.796-798.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.